Sigilon hold hurts ahead of key haemophilia meeting
After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.
No buyout for Uniqure
But a licensing deal with CSL could have underappreciated benefits, even if expectations were for something much bigger.
